The purpose of this mono therapy study is to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of BCD-145 (JSC BIOCAD, Russia) in patients with unresectable/metastatic melanoma.
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Anti-CTLA-4 monoclonal antibody (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Biocad
- 15 Apr 2019 Status changed from recruiting to completed.
- 23 Mar 2018 New trial record